Tenofovir Disoproxil

A nucleoside reverse transcriptase inhibitor (antiviral drug), which is used in the treatment of HIV infection. There is no cure for HIV infection, so the objective of the treatment is just to reduce the viral load for extended period of time. To obtain best possible results, it is given in combination with other antiretroviral drugs. Varrying degrees of cross-resistance to tenofovir may occur by preexisting Zidovudine-associated mutations (permanent changes in genetic material). Gastrointestinal complaints are the most common side effects, but usually do not require discontinuation of therapy.

Brands
TENOFO-B UNI-VIR TIFOWAN TENOVA TENOVA VIREAD VIREAD TENOFOVIR TENOVIR CARAFOVIR CARAFOVIR OFOVIR TENOVIR TENOVIR TENOWIN TENOWIN PANIV RICOVER Hebnores Soinvir
Adult Dose
Dose: 300 mg
Single Dose: 300 (300)
Frequency: As recommended.
Route: PO
Instructions:
Neonatal
Paedriatic
Characteristics
. It is of Semi Synthetic origin and belongs to Adenosine analog. It belongs to Antiviral Agents pharmacological group on the basis of mechanism of action.
Contraindications
Tenofovir Disoproxil is contraindicated in conditions like Breast feeding.
Effects
The symptomatic adverse reactions produced by Tenofovir Disoproxil are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Diarrhea, Nausea and vomiting, Hypophosphatemia.
Indications
Tenofovir Disoproxil is primarily indicated in conditions like HIV infection, HIV infection in combination with other antiretroviral drugs.
Interactions
No data regarding the interactions of Tenofovir Disoproxil was found.
Interfrence
Elevation in ALT or ASTElevated liver enzymes
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tabs Store in a well closed container, at room temperature, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.
Warnings
Tenofovir Disoproxil should be used with caution in patients with renal impairment, test renal function and serum phosphate before treatment, then every 4 weeks (weekly if given with nephrotoxic drug e.g cidofovir), interrupt treatment if renal function deteriorates or serum phosphate decreases; pregnancy (use only if potential benefit outweighs risk).
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.